MapLight Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric and CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
MapLight's lead candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic initially being developed for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP). The company is currently conducting two Phase 2 trials of ML-007C-MA: one for the treatment of schizophrenia, with topline results expected in the 2H26; and one for the treatment of ADP, with topline results expected in the 2H27.
The Redwood City, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol MPLT. MapLight Therapeutics filed confidentially on March 8, 2024. Morgan Stanley, Jefferies, Leerink Partners, and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
